clinical trial · NCT05885412
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)RP-A601
brief summary
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
started
Aug 29, 2023
primary completion
Sep 1, 2028
completion
Sep 1, 2029
last updated
Apr 16, 2026
official title
A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol